Skip to main content

The independent medical news service

Lung cancer

26-01-2022 | Oncology | News | Article

Radiotherapy futile add-on to durvalumab–tremelimumab in refractory NSCLC

Adding low-dose or hypofractionated radiotherapy to durvalumab plus tremelimumab offers no significant benefit to people with non-small-cell lung cancer that is resistant to PD-1 or PD-L1 inhibition, US study findings indicate.

24-01-2022 | Oncology | News | Article

Cutaneous irAEs linked to improved survival following ICI therapy

Cutaneous immune-related adverse events are associated with a reduced risk for death among cancer patients with immune checkpoint inhibitors, research suggests.

20-01-2022 | Oncology | Highlight | Article

Sugemalimab shows promise for locally advanced, metastatic NSCLC

The PD-L1 inhibitor sugemalimab has shown potential both as a consolidation treatment option for inoperable, locally advanced non-small-cell lung cancer as well as in combination with chemotherapy for the first-line treatment of metastatic disease.

18-01-2022 | Oncology | News | Article

Reassurance on radiotherapy use prior to ICI initiation

Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.

17-01-2022 | Oncology | News | Article

BMI may be key to unlocking metformin NSCLC benefit

A post-hoc analysis of a randomized trial points to the benefit of adding metformin to an EGFR–tyrosine kinase inhibitor in advanced non-small-cell lung cancer patients with a BMI of at least 24 kg/m2.

13-01-2022 | Oncology | News | Article

Meta-analysis confirms benefit of quitting smoking at lung cancer diagnosis

Quitting smoking around the time of receiving a lung cancer diagnosis is associated with significantly improved overall survival than continuing smoking, shows a meta-analysis published in the Journal of Thoracic Oncology.

07-01-2022 | Oncology | News | Article

Adding camrelizumab to first-line chemo improves squamous NSCLC outcomes

Treatment-naïve patients with advanced squamous non-small-cell lung cancer derive a significant progression-free survival and overall survival benefit with the addition of camrelizumab to chemotherapy, indicates the Chinese CameL-sq study.

05-01-2022 | Oncology | News | Article

ASCO releases guideline for stage III NSCLC management

Click through for more information

22-12-2021 | Oncology | News | Article

Tepotinib, lorlatinib receive EMA nod

Click through for more information about these non-small-cell lung cancer opinions

16-12-2021 | Oncology | News | Article

HLA-A*03 shows potential as a biomarker for ICI response

The risk for disease progression or death increases with HLA-A*03 allele count in people undergoing immune checkpoint inhibitor therapy for cancer, irrespective of tumor type and agent used, research suggests.

06-12-2021 | Oncology | News | Article

Vibostolimab ‘promising’ for advanced solid tumors

Vibostolimab given alone or in combination with pembrolizumab is well tolerated and demonstrates antitumor activity in patients with advanced solid tumors, including non-small-cell lung cancer, show results of a first-in-human study of the antibody targeting the TIGIT domain. 

03-12-2021 | Oncology | News | Article

Poziotinib shows potential for advanced NSCLC with HER2 exon 20 insertions

The tyrosine kinase inhibitor poziotinib has antitumor activity in heavily pretreated patients with advanced or metastatic non-small-cell lung cancer harboring HER2 exon 20 insertions, show data from the phase 2 ZENITH20 trial.

29-11-2021 | Oncology | News | Article

EMA backs sotorasib for KRAS-mutated advanced NSCLC

Click through for further information on this announcement

12-11-2021 | Oncology | News | Article

EGFR-positive NSCLC recurrence patterns explored

People with EGFR-positive non-small-cell lung cancer may benefit from individualized risk-profiling, say researchers who observed a high recurrence risk following resection but also identified a subgroup that may be cured without adjuvant osimertinib.

11-11-2021 | Oncology | News | Article

More support for integrating geriatric assessment-guided management into oncology care

Incorporating geriatric assessment-guided management into the care of older patients receiving anticancer therapy could reduce the risk for treatment toxicity and falls as well as polypharmacy, suggests a cluster randomized controlled trial.

08-11-2021 | Oncology | News | Article

ICI monotherapy benefits cancer patients aged 80 and older

Age alone should not preclude the use of immune checkpoint inhibitors in people with cancer aged 80 years or more, say researchers who found promising efficacy and tolerability of single-agent therapy in this patient population.

04-11-2021 | Oncology | News | Article

Real-world data support 2-year ICI duration in NSCLC

A high proportion of individuals with non-small-cell lung cancer who complete 2 years of immune checkpoint inhibitor treatment show durable responses after stopping treatment, show real-world data from Korea.

02-11-2021 | Oncology | News | Article

ASCO updates guidelines for managing immune-related adverse events

Read more about these clinical practice guidelines here

26-10-2021 | Oncology | News | Article

ICIs linked to increased venous thromboembolism risk

A large single-center study has found an association between immune checkpoint inhibitor use and an increased incidence of venous thromboembolism in people with cancer.

25-10-2021 | Oncology | News | Article

Chemotherapy-related toxic effects reduced with geriatric assessment-driven intervention

A geriatric assessment-driven intervention may reduce the risk for grade 3 or higher chemotherapy-related toxicities in older people with cancer, research suggests.

Image Credits